All In MedTech

Device Trial Radar · NCT07863739

CO₂ Laser With or Without Platelet-Rich Plasma for Genitourinary Syndrome of Menopause

Fractional CO₂ Laser Versus Combined CO₂ Laser and Platelet-Rich Plasma for the Management of Genitourinary Syndrome of Menopause: A Prospective Study.

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Jun 1, 2023

Primary completion

Apr 1, 2025

Study completion Apr 1, 2025

Sponsor

Lead sponsor
National and Kapodistrian University of AthensAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 7, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Female only, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluated whether adding platelet-rich plasma (PRP) to fractional CO₂ laser treatment provides additional benefit for postmenopausal women with genitourinary syndrome of menopause (GSM). Participants received either fractional CO₂ laser treatment alone or fractional CO₂ laser combined with PRP injections. Both groups received three treatment sessions at 4-6-week intervals. The main outcome was the change in vaginal dryness after treatment. Other outcomes included vaginal symptoms, sexual function, quality of life, and measures of vaginal health. The study also evaluated the safety and tolerability of both treatments.

Conditions

  • Genitourinary Syndrome of Menopause (GSM)

Interventions

  • Fractional CO₂ LaserDevice

    Fractional laser treatment was performed using the DEKA DUOGlide GYN system (DEKA M.E.L.A., Florence, Italy), combining CO₂ (10,600 nm) and 1540 nm wavelengths. Three treatment sessions were performed at 4-6-week intervals.

  • Autologous Platelet-Rich Plasma (PRP)Biological

    Autologous PRP was prepared from 40 mL of peripheral blood using the OMNIPLEX Gyno kit, yielding approximately 3 mL of PRP with a platelet concentration approximately nine times baseline. PRP was injected into predefined vaginal sites immediately after each laser treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Vaginal Dryness SeverityTime frame: Baseline to 1 month after the final treatment session

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Alexandra General Hospital

    Athens, Greece

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.